WA-AUTH0
12.1.2022 14:02:05 CET | Business Wire | Press release
Auth0 , a product unit within Okta (NASDAQ: OKTA), today released the findings of its first Public Sector Identity Index , a global research report that provides government technology leaders with insight into the identity maturity of public sector organizations around the world. The report highlights the importance of a centralized identity strategy in putting safe and accessible services into the hands of citizens faster.
Over the past two years, many public sector organizations were prompted by the immediate need to deploy digital infrastructure to maintain continuity of their services amid the COVID-19 pandemic — such as offering citizens license renewals online and virtual education — and are now grappling with the impacts on cybersecurity and user experience. From the Executive Order on ‘Improving the Nation’s Cybersecurity’ in the U.S., to digital identity and Single Sign-On (SSO) initiatives in the UK and Australia, enabling employees, citizens, and other government entities to access all of these applications easily and securely has become a demand around the world.
The 2022 Public Sector Identity Index, conducted by Auth0 and Market Connections , captures the perceptions of 850 IT and line of business decision-makers within national and state/local government organizations across the U.S., UK, and ANZ (Australia and New Zealand) with regard to their Identity and Access Management (IAM) strategy.
The report’s key findings include:
- Only one in five are extremely confident in either the security (17%) or ease of use (19%) of their current authentication solution.
- Username and password is the most frequently used authentication method by citizens (86%), compared to very little usage of biometric or passwordless authentication (16%).
- Four in ten are currently building their own IAM solution in-house (41%), and cite speed to implementation (83%) and using internal staff to manage IAM internally (82%) as two of the biggest pain points in doing so.
- Most governments are looking to expand their digital services in the next two years (75%) and rank protecting citizen’s privacy and data as most important when thinking about citizen services (73%).
Regional analysis shows U.S. respondents rank ensuring citizens’ trust in digital services as an area of high importance (71%), but have less confidence in their organization’s ability to deliver this (56%). Similar discrepancies in importance versus confidence in delivery include speed in adding new services in the UK (66% importance vs. 48% confidence), and improving the user experience in ANZ (72% importance vs. 60% confidence).
Dean Scontras, Vice President of State and Local Government and Education (SLED) at Okta, said: “Digitization is likely to continue in light of Zero Trust mandates and mounting consumer expectations. Public sector organizations greatly benefit from bringing their identity management strategy in line with their digital goals. While there is a strong focus on securing citizen data, the vast majority of applications are still protected by a username and password, despite their well-documented security risks.”
According to Forrester Research, the public sector has a massive influence on the entire economy making up 30% of the global GDP and 33% of the global workforce, and the global research firm predicts that more governments will adopt Zero Trust frameworks to revive public trust in digital services.1
An Identity-First approach puts identity at the center of government digital transformation, while also laying the foundation for a Zero Trust security model. Key to this approach are modern login technologies that replace traditional passwords, and introduce friction only when suspicious behavior is detected. By making the shift to Identity-First, organizations like Larimer County provide easy and seamless access for legitimate users, while decreasing the risk of security and compliance breaches.
Jessica Figueras, a cybercrime and digital identity advisor to governments and Okta consultant, said: “In the face of increasing digitization, skills shortages, and online harms, governments are taking a hard look at the technologies they can bring onboard to help them reach their digital goals. The research suggests that identity is one such technology that can help the public sector do more with less.”
To learn more and download the full report, please visit: 2022 Auth0 Public Sector Identity Index .
Methodology
Auth0 engaged Market Connections to design an online survey of 850 IT and line of business decision-makers within national and state/local governments in the U.S. (200 federal, 200 state & local), UK (100 federal, 100 state & local), and ANZ (Australia and New Zealand) (155 federal/national, 95 state & local), fielded in September-October 2021.
About Auth0
Auth0, a product unit within Okta, takes a modern approach to identity and enables organizations to provide secure access to any application, for any user. The Auth0 Identity Platform is highly customizable, and is as simple as development teams want, and as flexible as they need. Safeguarding billions of login transactions each month, Auth0 delivers convenience, privacy, and security so customers can focus on innovation. For more information, visit https://auth0.com .
About Okta
Okta is the leading independent identity provider. The Okta Identity Cloud enables organizations to securely connect the right people to the right technologies at the right time. With more than 7,000 pre-built integrations to applications and infrastructure providers, Okta provides simple and secure access to people and organizations everywhere, giving them the confidence to reach their full potential. More than 14,000 organizations, including JetBlue, Nordstrom, Siemens, Slack, Takeda, Teach for America, and Twilio, trust Okta to help protect the identities of their workforces and customers.
Disclaimer:
Research reports and related summaries referenced herein are provided for informational purposes only, and consist of the opinions of the organizations publishing such research and should not be construed as statements of fact. Okta and Auth0 make no representations, warranties, or other assurances with respect to such research.
1 Public Sector Predictions 2022, Forrester Research, Inc., November 3, 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
